[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"erythema\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:erythema":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100629454","early-phase-1-efficacy-of-05-topical-timolol-eye-drops-in-the-treatment-of-post-inflammatory-erythema-following-acne-vulgaris-100629454",false,"NCT07474883","Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris","Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris: A Comparative Study With Intense Pulsed Light (IPL)","Inclusion Criteria: Participants must meet all of the following criteria:\n\n* Age ≥ 12 years with a history of acne vulgaris.\n* Clinically diagnosed with post-inflammatory erythema (PIE) secondary to acne vulgaris.\n* Willing and able to provide informed consent (or assent with parental\u002Fguardian consent if under 18 years of age).\n\nExclusion Criteria:\n\n* Refusal to participate or inability to comply with study procedures (examinations, treatment, follow-up visits), or loss to follow-up.\n* Presence of post-inflammatory hyperpigmentation (PIH) at the study site that may interfere with accurate assessment of erythema.\n* Presence of other dermatologic conditions affecting the treatment area (e.g., atopic dermatitis, rosacea, lupus erythematosus).\n* Known hypersensitivity or adverse reaction to timolol or other beta-adrenergic receptor blockers.\n* Pregnant or breastfeeding women.\n* History of cardiovascular or respiratory conditions contraindicating beta-blocker use (e.g., asthma, atrioventricular block, bradycardia \\\u003C50 beats per minute, hypotension).\n* Use of other topical medications or cosmetic products (except sunscreen) on the study area during the study period.","ALL","12 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","Post-inflammatory erythema (PIE) is a common sequela of acne vulgaris, characterized by persistent erythematous macules resulting from superficial vascular dilation. Current treatment options include energy-based devices such as intense pulsed light (IPL); however, these modalities may be costly and require specialized equipment.\n\nTimolol, a non-selective beta-adrenergic receptor blocker, has demonstrated vasoconstrictive properties and has been used off-label in dermatology for vascular-related conditions. This study aims to evaluate the efficacy and safety of topical 0.5% timolol ophthalmic solution in improving post-inflammatory erythema secondary to acne vulgaris and to compare its clinical outcomes with those achieved by intense pulsed light (IPL) therapy.\n\nThis prospective comparative study will assess changes in erythema severity using standardized clinical evaluation and objective measurement tools over a defined treatment period. The findings may provide evidence for a cost-effective and accessible therapeutic alternative for managing post-acne erythema.",[26,27,28],"Post Inflammtory Erythema","Acne Vulgaris","Erythema","RECRUITING","2026-03-26",{"date":32,"type":33},"2026-04-01","ACTUAL",{"date":35,"type":20},"2026-03-09",{"date":37,"type":20},"2026-10-09",{"name":39,"class":40},"Pham Ngoc Thach University of Medicine","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":41},"100619482","the-effect-of-16-week-dietary-intake-of-food-supplements-containing-collagen-and-msm-on-facial-erythema-and-other-skin-parameters-100619482","NCT07345195","The Effect of 16-week Dietary Intake of Food Supplements Containing Collagen and MSM on Facial Erythema and Other Skin Parameters","The Effect of 16-week Dietary Intake of Food Supplements Containing Collagen and MSM on Facial Erythema and Other Skin Parameters: Double Blind, Placebo-controlled, Randomised Three-way Study Comparing the Efficacy of Two Test Products","TO-COSKIN4","Inclusion criteria:\n\n* Caucasian female volunteers aged 35 to 65 years at the time of signing the Informed Consent Form (ICF).\n* Signed Informed Consent Form (ICF).\n* Fitzpatrick skin phototypes I-IV.\n* Presence of visible signs of skin ageing.\n* Presence of visible facial telangiectasias, primarily on the cheeks.\n* Presence of facial erythema with a baseline score ≤ 3 on the 5-point Clinical Erythema Assessment (CEA) scale.\n* Stable erythema-prone facial skin for at least 3 months prior to study inclusion, without clinical signs of active rosacea.\n* In good general health, as determined by medical history.\n* Body Mass Index (BMI) \\\u003C 35.\n* Willingness and ability to:\n\n  * Comply with all study procedures and complete a subject diary.\n  * Maintain usual lifestyle habits throughout the study.\n  * Not initiate or modify oestrogen or progesterone therapies during the study.\n  * Maintain the same cosmetic and skincare routine and comply with sun protection guidelines throughout the study.\n  * Avoid rejuvenation treatments during the study.\n  * Refrain from consuming food supplements containing collagen or other protein-based supplements, methylsulfonylmethane (MSM), or anti-inflammatory and\u002For antioxidant compounds with a known or potential impact on skin inflammation or vascular response for the duration of the study.\n\nExclusion criteria:\n\n* Pregnancy or breastfeeding.\n* Vegan diet.\n* Heavy smoking or frequent alcohol-induced flushing.\n* Occupational or hobby-related excessive heat exposure (e.g. chefs, sauna workers) likely to interfere with vascular stability.\n* Anticipated sunbathing or solarium use, or major planned changes in sun exposure before or during the study.\n* Planned major changes during the study in:\n\n  * Skincare routine\n  * Hormonal therapy (contraception or hormone replacement therapy)\n* Significant changes in dietary habits or dietary supplementation within 3 months prior to inclusion.\n* Regular use within 3 months prior to inclusion of food supplements containing:\n\n  * Methylsulfonylmethane (MSM);\n  * Collagen or other protein-based supplements;\n  * Anti-inflammatory supplements (e.g. bioflavonoids\u002Frutin, curcumin, EPA) and\u002For antioxidant supplements with a known or potential impact on skin inflammation or vascular response.\n* Any diagnosed, uncontrolled, untreated, or unstable medical condition.\n* Clinically significant history of metabolic, gastrointestinal, hepatic, renal, or haematological disease.\n* Mental incapacity or psychiatric condition that may impair understanding of the study or compliance with study requirements.\n* Any clinically significant acute or chronic inflammatory skin disease, including but not limited to acne, perioral dermatitis, psoriasis, atopic dermatitis, or lupus.\n* Skin pigmentation disorders at the assessment sites.\n* Active rosacea within 3 months prior to study entry, defined as the presence of papules\u002Fpustules, frequent flushing episodes typical of rosacea, or ocular involvement.\n* Frequent vasomotor hot flushes (e.g. perimenopausal or menopausal), which may interfere with erythema assessments.\n* Use of medications affecting skin or vascular reactivity, including but not limited to: systemic corticosteroids, anticoagulants (e.g. coumarins, heparin), vasodilators (e.g. hydralazine, nitroglycerin), antibiotics with potential to affect erythema or vascular response, immunomodulators, regular or long-term use of non-steroidal anti-inflammatory drugs (NSAIDs)\n* Use of systemic retinoids within 3 months prior to study entry.\n* Changes of skin care routine regimen within 4 weeks prior to study entry.\n* Use of highly concentrated topical products (\\>15% azelaic acid, 10% vitamin C…) affecting inflammatory or vascular facial responses within 4 weeks prior to study entry.\n* Invasive rejuvenation treatments (e.g. medium or deep chemical peels, ablative or vascular laser therapies) within 6 months prior to study entry.\n* Non-invasive or minimally invasive rejuvenation treatments (e.g. microneedling, mesotherapy, superficial chemical peels, radiofrequency, electrotherapy, ultrasound, IPL) within 3 months prior to study entry.\n* Known or suspected allergy to any ingredient of the investigational product(s).",true,"FEMALE","35 Years","65 Years",{"count":55,"type":20},90,[57],"NA","The aim of this study is to compare the effects of 16 weeks of daily dietary supplementation with two investigational products containing collagen, methylsulfonylmethane (MSM), and vitamin C on skin parameters in comparison to a placebo product. The study will be conducted in healthy human subjects with visible facial erythema and telangiectasiae (cheeks), stable for ≥3 months, without active rosacea.\n\nThe primary objective is to demonstrate beneficial effects of the investigational products on facial erythema.\n\nThe secondary objective is to evaluate the effect of the investigational products on facial telangiectasiae severity.\n\nOther skin parameters will be assessed as supportive endpoints, and differences in efficacy between the two investigational formulations will also be evaluated.",[28,60,61],"Telangiectasis","Skin Redness",[63,28,64,65,66,67,68,69,70],"Facial telangiectasiae","Facial erythema","Collagen","MSM","Dietary supplement","Skin health","Skin redness","Erythema-prone skin","NOT_YET_RECRUITING","2026-01-08",{"date":74,"type":33},"2026-01-15",{"date":76,"type":20},"2026-01",{"date":78,"type":20},"2026-11",{"name":80,"class":40},"VIST - Faculty of Applied Sciences"]